Embla Medical hf: Interim Report Q3 2024

22 October 2024

COPENHAGEN, Denmark, Oct. 22, 2024 /PRNewswire/ -- 

Sveinn Sölvason, President and CEO, comments:

"We delivered solid sales in the third quarter amounting to USD 214 million. Organic sales growth was 7% and local currency growth was 11%. The strong momentum we have seen in EMEA throughout 2024 continued driven by strong performance in Prosthetics & Neuro Orthotics and Patient Care. In our Bracing & Supports business growth was more modest for the quarter.

As of September 1, 2024, US Medicare has expanded access to advanced bionics for K2 patients. Healthcare professionals are currently assessing first patients as part of the replacement cycle through medical documentation that a bionic knee would improve the patient's functional health outcomes.

Our EBITDA margin came in strong for the quarter at 22%. We continue to see the positive effects from the cost reduction initiatives implemented in manufacturing earlier this year as well as contribution from better product mix and cost control.

We are executing well on our Growth'27 strategy and reiterate our full year guidance of 6-8% organic sales growth and ~20% EBITDA margin before special items."

Highlights Q3 2024

Other highlights

2024 outlook

Conference call details

Embla Medical will host a conference call on October 22, 2024, at 9:00 CET / 7:00 GMT / 3:00 EST.

The conference call webcast can be accessed through following link:
https://edge.media-server.com/mmc/p/o2dxucfe

To actively participate in the Q&A session of the call please use following link for dial in options
ttps://register.vevent.com/register/BI0f67d9e43c4f4ff484123ef1cff5e472

The latest investor presentation can be downloaded through following link Embla Medical Reports & Presentations

Further information
Klaus Sindahl, Head of Investor Relations, [email protected], +45 5363 0134

Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors

About Embla Medical

Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women's Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com 

Embla Medical was formerly listed as Össur (OSSR) on Nasdaq Copenhagen until 8 April 2024.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--interim-report-q3-2024,c4054217

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/embla-medical-hf-interim-report-q3-2024-302282667.html